340 related articles for article (PubMed ID: 33581500)
1. Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet's uveitis with vasculitis.
Yang S; Huang Z; Liu X; Li H; Xie L; Chen X; Wen F; Liang D; Su W
Int Immunopharmacol; 2021 Apr; 93():107430. PubMed ID: 33581500
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet's Retinal Vasculitis.
Yang S; Huang Z; Hu Y; Zhang J; Liu X; Li H; Xie L; Wen F; Liang D; Su W
Front Pharmacol; 2021; 12():609148. PubMed ID: 34239438
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Vannozzi L; Lopalco G; Guerriero S; Orlando I; Franceschini R; Bacherini D; Cimino L; Soriano A; Frediani B; Galeazzi M; Iannone F; Tosi GM; Salvarani C; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):183-189. PubMed ID: 27853889
[TBL] [Abstract][Full Text] [Related]
4. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
[TBL] [Abstract][Full Text] [Related]
5. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease.
Martín-Varillas JL; Calvo-Río V; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Garfella MH; Pascual EV; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; Salom D; Ortego N; García-Serrano JL; Callejas-Rubio JL; Herreras JM; García-Aparicio Á; Maíz O; Blanco A; Torre I; Díaz-Valle D; Pato E; Aurrecoechea E; Caracuel MA; Gamero F; Minguez E; Carrasco-Cubero C; Olive A; Vázquez J; Ruiz-Moreno O; Manero J; Muñoz-Fernández S; Martinez MG; Rubio-Romero E; Toyos-Sáenz de Miera FJ; López Longo FJ; Nolla JM; Revenga M; González-Vela C; Loricera J; Atienza-Mateo B; Demetrio-Pablo R; Hernández JL; González-Gay MA; Blanco R
Ophthalmology; 2018 Sep; 125(9):1444-1451. PubMed ID: 29602570
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies.
Fabiani C; Sota J; Rigante D; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Bitossi A; Orlando I; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2018 Oct; 37(10):2805-2809. PubMed ID: 29766375
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behçet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation.
Evereklioglu C; Sonmez HK; Sevim DG; Arda H; Sener H; Polat OA; Horozoglu F
Int Ophthalmol; 2023 Dec; 43(12):4461-4472. PubMed ID: 37555889
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome.
Silvestri E; Bitossi A; Bettiol A; Emmi G; Urban ML; Mattioli I; Di Scala G; Bacherini D; Lopalco G; Venerito V; Iannone F; Vitale A; Tosi GM; Rizzo S; Fabiani C; Cantarini L; Virgili G; Vannozzi L; Prisco D
Inflammopharmacology; 2020 Jun; 28(3):711-718. PubMed ID: 32157555
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
12. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
Interlandi E; Leccese P; Olivieri I; Latanza L
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.
Barroso-García N; Atienza-Mateo B; Ferraz-Amaro I; Prieto-Peña D; Beltrán E; Adán A; Hernández-Garfella M; Martínez-Costa L; Cordero-Coma M; Díaz-Llopis M; Herreras JM; Maíz-Alonso O; Torre-Salaberri I; De Vicente-Delmás A; Díaz-Valle D; Atanes-Sandoval A; Francisco F; Insua S; Sánchez J; Almodóvar-González R; Jiménez-Sosa A; Ruiz-Moreno O; Gandía-Martínez M; Nolla JM; Calvo-Río V; Castañeda S; González-Gay MA; Blanco R
Semin Arthritis Rheum; 2023 Feb; 58():152153. PubMed ID: 36549244
[TBL] [Abstract][Full Text] [Related]
15. Ultra-Widefield Fluorescein Angiography to Monitor Therapeutic Response to Adalimumab in Behcet's Uveitis.
Kim BH; Park UC; Park SW; Yu HG
Ocul Immunol Inflamm; 2022 Aug; 30(6):1347-1353. PubMed ID: 33793368
[TBL] [Abstract][Full Text] [Related]
16. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.
Vallet H; Seve P; Biard L; Baptiste Fraison J; Bielefeld P; Perard L; Bienvenu B; Abad S; Rigolet A; Deroux A; Sene D; Perlat A; Marie I; Feurer E; Hachulla E; Fain O; Clavel G; Riviere S; Bouche PA; Gueudry J; Pugnet G; Le Hoang P; Resche Rigon M; Cacoub P; Bodaghi B; Saadoun D;
Arthritis Rheumatol; 2016 Jun; 68(6):1522-30. PubMed ID: 27015607
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-α Therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients.
Kunimi K; Usui Y; Asakage M; Maehara C; Tsubota K; Mitsuhashi R; Umazume A; Kezuka T; Sakai JI; Goto H
Ocul Immunol Inflamm; 2022 Jan; 30(1):223-230. PubMed ID: 32815752
[TBL] [Abstract][Full Text] [Related]
18. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
Maalouf G; Andrillon A; Leclercq M; Sève P; Bielefeld P; Gueudry J; Sené T; Titah C; Moulinet T; Rouvière B; Sène D; Desbois AC; Domont F; Touhami S; Thibault T; Chamieh CE; Cacoub P; Kodjikian L; Biard L; Bodaghi B; Saadoun D
Am J Ophthalmol; 2022 Jun; 238():173-180. PubMed ID: 35172172
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Adalimumab in Patients with Behçet Uveitis: A Systematic Review and Meta-Analysis.
Sener H; Evereklioglu C; Horozoglu F; Gunay Sener AB
Ocul Immunol Inflamm; 2024 Jan; 32(1):89-97. PubMed ID: 36625549
[TBL] [Abstract][Full Text] [Related]
20. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
